The three standardised regimens potentially able to manage the different categories of TB cases
| TB patients categories | Standardised treatment regimen | Recommendations |
| 1. Standardised treatment regimen for patients with rifampicin-susceptible TB | 2 HRZE#/4 HR | #: In case of a positive sputum smear microscopy at the end of the second month of treatment, consider to check susceptibility to isoniazid before switching to the continuation phase (isoniazid, rifampicin) |
| 2. Standardised treatment regimen for RR/MDR-TB patients, susceptible to FQs and SLIs | 4 Km-hMfx¶-Cfz-Eto/Pto-Z-E-hH+/5 hMfx¶-Cfz-E-Z | Standardised shortened treatment with SLD The intensive phase should be extended to 6 months when at the end of the fourth month of treatment, sputum smear microscopy is still positive ¶: HMfx (600–800 mg·day−1) +: hH (15 mg·kg−1 body weight) |
| 3. Standardised treatment regimen for patients with pre-XDR-TB and XDR-TB | Lzd-Bdq-Mrp/Clav (or Dlm)-Cfz- Amk§-hLfx§-hH§ | §: With the considerations on duration and possible change of drugs exposed in the text |
TB: tuberculosis; H: isoniazid; R: rifampicin; Z: pyrazinamide; E: ethambutol; RR: rifampicin-resistant; MDR: multidrug-resistant; Km: kanamycin; hMfx: high-dose moxifloxacin; Cfz: clofazimine; Eto: ethionamide; Pto: prothionamide; hH: high-dose isoniazid; SLD: second-line drug; XDR: extensively drug-resistant; Lzd: linezolid; Bdq: bedaquiline; Mrp/Clav: meropenem/clavulanate; Dlm: delamanid; Amk: amikacin; hLfx: high-dose levofloxacin.